{"id":1360,"date":"2000-08-01T12:00:00","date_gmt":"2000-08-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse"},"modified":"2022-03-17T14:09:38","modified_gmt":"2022-03-17T13:09:38","slug":"neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/neues-in-der-behandlung-des-akuten-myokardinfarkts-der-streit-um-akut-ptca-oder-thrombolyse","title":{"rendered":"Neues in der Behandlung des akuten Myokardinfarkts? Der Streit um Akut-PTCA oder Thrombolyse"},"content":{"rendered":"<p>Die Reperfusions-Therapie beim akuten Myokardinfarkt ist nach wie vor ein umstrittenes Thema. Wir hatten uns bereits 1995 ausf\u00fchrlich damit besch\u00e4ftigt (AMB 1995, 29, 57 und 65). K\u00fcrzlich ver\u00f6ffentlichte die offizielle Zeitschrift der \u00c4rztekammer Berlin einen lesenswerten Diskussionsbeitrag von K.-P. Sch\u00fcren (1). Die Argumente f\u00fcr und gegen verschiedene Behandlungsverfahren und die neuen Entwicklungen werden hier mit [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Reperfusions-Therapie beim akuten Myokardinfarkt ist nach wie vor ein umstrittenes Thema. Wir hatten uns bereits 1995 ausf\u00fchrlich damit besch\u00e4ftigt (AMB 1995, 29, 57 und 65). K\u00fcrzlich ver\u00f6ffentlichte die offizielle Zeitschrift der \u00c4rztekammer Berlin einen lesenswerten Diskussionsbeitrag von K.-P. Sch\u00fcren (1). Die Argumente f\u00fcr und gegen verschiedene Behandlungsverfahren und die neuen Entwicklungen werden hier mit [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1464,2610,82,3286,3284,3285,730,729,1785,3290,71,687,3291,1172,85,86,3289,88,89,65,3288,3287,83,84,87,79,3278,372,369,3281,3279,3283,882,3277,78,80,727,3282,3280,81],"class_list":["post-1360","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abciximab","tag-admiral-studie","tag-alteplase","tag-assent-i-studie","tag-compass-studie","tag-escobar-studie","tag-gp-iib-iiia-rezeptor-antagonisten","tag-gp-iib-iiia-rezeptor-blocker","tag-gusto-iib-studie","tag-gusto-iii-studie","tag-herzinfarkt","tag-hirudin","tag-intime-studie","tag-koronar-stent","tag-koronarangiografie","tag-koronarangiographie","tag-lanoteplase","tag-lysetherapie","tag-miti-studie","tag-myokardinfarkt","tag-npa","tag-nrmi-2-register","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-ptca","tag-rapport-studie","tag-reteplase","tag-rpa","tag-saruplase","tag-shock-studie","tag-speed-studie","tag-stent","tag-stent-pami-studie","tag-streptokinase","tag-thrombolysetherapie","tag-thrombozytenaggregationshemmer","tag-timi-14-studie","tag-tnk-tpa","tag-tpa"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1360"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1360\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}